Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.514
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 3, March, p. 339–346

doi: 10.17219/acem/79296

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Potential plasma biomarkers of bladder cancer identified by proteomic analysis: A pilot study

Anna Lemańska-Perek1,A,B,C,D,F, Jolanta Lis-Kuberka1,A,B,C,D,F, Adam Lepczyński2,B,C,E,F, Alicja Dratwa-Chałupnik2,B,C,E,F, Krzysztof Tupikowski3,4,E,F, Iwona Kątnik-Prastowska1,C,E,F, Małgorzata Ożgo2,B,C,E,F

1 Department of Chemistry and Immunochemistry, Wroclaw Medical University, Poland

2 Department of Physiology, Cytobiology and Proteomics, West Pomeranian University of Technology, Szczecin, Poland

3 Department of Urology and Oncologic Urology, Wroclaw Medical University, Poland

4 Department of Oncologic Urology, Lower Silesian Oncology Center, Wrocław, Poland

Abstract

Background. Bladder cancer diagnosis and surveillance includes cystoscopy and cytology. New methods for the detection of bladder cancer are needed, because cystoscopy is invasive and expensive, and because urine cytology is not sensitive enough.
Objectives. The aim of the study was to select potential plasma protein markers for bladder cancer which could be useful in developing a specific laboratory test to improve diagnosis and to establish treatment strategies in order to prevent the recurrence of the disease.
Material and Methods. Plasma proteome maps were prepared based on 2-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), combined with image gel analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry of plasma samples from patients with urothelial bladder cancer, and they were compared to normal samples.
Results. The analyses of bladder cancer plasma samples allowed us to distinguish 3 groups of proteins whose relative abundance differed from that in normal samples. The 1st one comprised modified forms of plasma transferrin, fibrinogen gamma and complement C3b, which were absent in normal plasma. The 2nd group comprised haptoglobin, alpha-2-macroglobulin, vitamin D-binding protein, and pigment epithelium-derived factor, which occurred in the cancerous samples in large quantities. The 3rd group consisted of 3 molecular forms of immunoglobulin M (IgM), the relative abundance of which was significantly lower in the cancerous plasma samples.
Conclusion. The data indicated potential plasma biomarkers associated with inflammation, immunity and coagulation processes accompanying bladder cancer. They could be used for the development of a laboratory test(s) useful in clinical practice.

Key words

bladder cancer, biomarkers, proteomics, blood plasma glycoproteins, 2-dimensional gel electrophoresis

References (40)

  1. Kaufman D, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009; 374(9685):239–249.
  2. Yang N, Feng S, Shedden K, et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res. 2011;17(10):3349–3359.
  3. Goodison S, Rosser ChJ, Urquidi V. Bladder cancer detection and monitoring: Assessment of urine- and blood-based marker tests. Mol Diagn Ther. 2013;17(2):71–84.
  4. Gutiérrez Baños JL, del Henar Rebollo Rodrigo M, Antolín Juárez FM, García BM. Usefulness of the BTA STAT test for the diagnosis of bladder cancer. Urology. 2001;57(4):685–689.
  5. Chang YH, Wu CH, Lee YL, Huang PH, Kao YL, Shiau MY. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Urology. 2004;64(4):687–692.
  6. Kageyama S, Isono T, Iwaki H, et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem. 2004;50(5):857–866.
  7. Santoni M, Catanzariti F, Minardi D, et al. Pathogenic and diagnostic potential of BLCA-1 and BLCA-4 nuclear proteins in urothelial cell carcinoma of human bladder. Adv Urol. 2012;2012. doi: 10.1155/2012/397412
  8. Willson CJ, Flake GP, Sills RC, Kissling GE, Cesta MF. Immunohistochemical expression of cyclin D1, cytokeratin 20, and uroplakin III in proliferative urinary bladder lesions induced by o-nitroanisole in Fischer 344/N rats. Vet Pathol. 2016;53(3):682–690.
  9. Menéndez V, Fernández-Suárez A, Galán JA, Pérez M, García-López F. Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology. 2005;65(2):284–289.
  10. Tiveron RC, de Freitas LC, Figueiredo DL, Serafini LN, Mamede RC, Zago MA. Expression of calcium binding protein S100 A7 (psoriasin) in laryngeal carcinoma. Braz J Otorhinolaryngol. 2012;78(4):59–65.
  11. Irmak S, Tilki D, Heukeshoven J, et al. Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics. 2005;25(16):4296–4304.
  12. Vasala K, Kuvaja P, Turpeenniemi-Hujanen T. Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer. Tumour Biol. 2008;29(5):279–286.
  13. Szarvas T, László V, Vom Dorp F, et al. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients’ prognosis in bladder cancer. Int J Cancer. 2012;130(12):2922–2929.
  14. Matsumoto K, Shariat SF, Casella R, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003;170(6 Pt 1):2248–2252.
  15. Washino S, Hirai M, Matsuzaki A, Kobayashi Y. Clinical usefulness of CEA, CA19-9, and CYFRA 21–1 as tumor markers for urothelial bladder carcinoma. Urol Int. 2011;87(4):420–428.
  16. Orenes-Piñero E, Cortón M, González-Peramato P, et al. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res. 2007;6(11):4440–4448.
  17. Røtterud R, Malmström PU, Wahlqvist R, Taskén KA. The star chart to Ta bladder cancer: An unsophisticated analysis of two-dimensional gel electrophoresis proteome maps. Scand J Urol Nephrol. 2010;44(2):76–83.
  18. Lee YR, Chen YW, Tsai MC, Chou HC, Chan HL. Redox- and expression-proteomic analysis of plasma biomarkers in bladder transitional cell carcinoma. Mol Biosyst. 2012;8(12):3314–3324.
  19. Sobin LH, Gospodarowicz MK, Wittekin Ch, eds. TNM Classification of Malignant Tumours. 7th ed. Hoboken, NJ: Union for International Cancer Control (UICC) & Wiley-Blackwell; 2009.
  20. Bladder urothelial nonneoplastic lesions WHO/ISUP classification 2004. http://www.pathologyoutlines.com/topic/bladderwhoisup.html. Accessed February 13,2017.
  21. Lepczyński A, Herosimczyk A, Ożgo M, et al. Dietary supplementation with dried chicory root triggers changes in the blood serum proteins engaged in the clotting process and the innate immune response in growing pigs. J Physiol Pharmacol. 2015;66(1):47–55.
  22. Ożgo M, Lepczyński A, Herosimczyk A. Two-dimensional gel-based serum protein profile of growing piglets. Turk J Biol. 2015;39(2):320–327.
  23. Caraux G, Pinloche S. PermutMatrix: A graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics. 2005;21(7):1280–1281.
  24. Yoon SJ, Park SY, Pang PC, et al. N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs benign prostate diseases. Int J Oncol. 2010;36(1):193–203.
  25. Chun RF. New perspectives on the vitamin D binding protein. Cell Biochem Funct. 2012;30(6):445–456.
  26. Feige JJ, Negoescu A, Keramidas M, Souchelnitskiy S, Chambaz EM. Alpha 2-macroglobulin: A binding protein for transforming growth factor-beta and various cytokines. Horm Res. 1996;45(3-5):227–232.
  27. Liu J, Li D, Cao L, et al. Elevated preoperative plasma fibrinogen level is an independent predictor of malignancy and advanced stage disease in patients with bladder urothelial tumors. Int J Surg. 2016;36 (Pt A):249–254.
  28. Halder S, Dey RK, Chowdhury AR, Bhattacharyya P, Chakrabarti A. Differential regulation of urine proteins in urothelial neoplasm. J Proteomics. 2015;127(Pt A):185–192.
  29. Ramadass M, Ghebrehiwet B, Kew RR. Enhanced recognition of plasma proteins in a non-native state by complement C3b. A possible clearance mechanism for damaged proteins in blood. Mol Immunol. 2015;64(1):55–62.
  30. Chen L, DiPietro LA. Production and function of pigment epithelium-derived factor in isolated skin keratinocytes. Exp Dermatol. 2014;23(6):
  31. Baxter RC. IGF binding proteins in cancer: Mechanistic and clinical insights. Nat Rev Cancer. 2014;14(5):329–341.
  32. Ujvari B, Hamede R, Peck S, et al. Immunoglobulin dynamics and cancer prevalence in Tasmanian devils (Sarcophilus harrisii). Sci Rep. 2016;6:25093.
  33. Li H, Li C, Wu H, et al. Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma. Proteome Sci. 2011;9:21.
  34. Frantzi M, Latosinska A, Flühe L, et al. Developing proteomic biomarkers for bladder cancer: Towards clinical application. Nat Rev Urol. 2015;12(6):317–330.
  35. Lepczyński A, Herosimczyk A, Ożgo M, et al. Dietary chicory root and chicory inulin trigger changes in energetic metabolism, stress prevention and cytoskeletal proteins in the liver of growing pigs: A proteomic study. J Anim Physiol Anim Nutr (Berl). 2016;66(1):47–55.
  36. Varki A, Kannagi R, Toole BP. Glycosylation changes in cancer. In: Varki A, Cummings RD, Esko JD, et al., eds. Essentials of Glycobiology. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009.
  37. Zhang L, Zhao F, Liang Z, et al. Effect of anti-human IgM antibody on the proliferation, apoptosis and cell cycle of Hep-2 laryngeal squamous cell carcinoma cells and potential mechanisms underlying its antitumor activity. Int J Clin Exp Pathol. 2017;10(2):858–868.
  38. Speeckaert MM, Speeckaert R, van Geel N, Delanghe JR. Vitamin D binding protein: A multifunctional protein of clinical importance. Adv Clin Chem. 2014;63:1–57.
  39. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer. 2012;107(9):1589–1594.
  40. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.